Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Otitis Media - Overview
Otitis Media - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Otitis Media - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Otitis Media - Companies Involved in Therapeutics Development
Ceolia Pharma Co Ltd
Clarametyx Biosciences Inc
Earno LLC
Eledon Pharmaceuticals Inc
Furen Pharmaceutical Group Co Ltd
Hun Sanqing Pharmaceutical Co Ltd
Laboratorios Salvat SA
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
MyX Therapeutics Inc
NTC srl
O-Ray Pharma Inc
Olymvax Biopharmaceuticals Inc
ProclaRx LLC
Vaxcyte Inc
Vyome Therapeutics Inc
Yuhan Corp
Otitis Media - Drug Profiles
(cholesteryl palmitate + colfosceril palmitate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ciprofloxacin hydrochloride + fluocinolone acetonide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(dexamethasone + piperacillin + tazobactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aspoxicillin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMTX-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMTX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fifloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTC-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OR-404IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCL-1440 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal (13-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal (23-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Peptide to Inhibit D for Otitis Media and Haemophilus Influenzae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tebipenem pivoxil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
V-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAX-24 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAX-XP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1917 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Otitis Media - Dormant Projects
Otitis Media - Product Development Milestones
Featured News & Press Releases
Jan 13, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement update on an investigatiol ear drug product
Jun 01, 2020: Novus Therapeutics announces topline results of phase 2a clinical trial of OP0201 in acute otitis media
Mar 02, 2020: Novus Therapeutics completes enrollment of Phase 2a trial of OP0201 in pediatric patients with acute otitis media
Jan 13, 2020: Novus Therapeutics provides update on OP0201
Oct 29, 2019: Novus Therapeutics receives FDA guidance on OP0201 phase 2a study in patients with Chronic Otitis Media with Effusion
Jun 10, 2019: Novus Therapeutics to present OP0201 data at the 20th intertiol symposium on recent advances in otitis media
Apr 23, 2019: Novus’ Phase I trials of otitis media drug meet primary objective
Feb 20, 2019: Novus Therapeutics begins dosing in otitis media drug trial
Feb 11, 2019: Novus Therapeutics doses first subjects in phase 1 pharmacodymics study of OP0201
Jan 30, 2019: Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials
Jan 10, 2019: Novus doses first patient in Phase I trial of OP0201
Dec 04, 2018: Novus Therapeutics announces formation of Scientific Advisory Board
Nov 28, 2018: Novus Therapeutics doses first subject in Phase I trial of OP0201
Jun 19, 2018: Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media
Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Otitis Media, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Otitis Media, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Otitis Media - Pipeline by Ceolia Pharma Co Ltd, 2021
Otitis Media - Pipeline by Clarametyx Biosciences Inc, 2021
Otitis Media - Pipeline by Earnano LLC, 2021
Otitis Media - Pipeline by Eledon Pharmaceuticals Inc, 2021
Otitis Media - Pipeline by Furen Pharmaceutical Group Co Ltd, 2021
Otitis Media - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, 2021
Otitis Media - Pipeline by Laboratorios Salvat SA, 2021
Otitis Media - Pipeline by Merck & Co Inc, 2021
Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, 2021
Otitis Media - Pipeline by MyX Therapeutics Inc, 2021
Otitis Media - Pipeline by NTC srl, 2021
Otitis Media - Pipeline by O-Ray Pharma Inc, 2021
Otitis Media - Pipeline by Olymvax Biopharmaceuticals Inc, 2021
Otitis Media - Pipeline by ProclaRx LLC, 2021
Otitis Media - Pipeline by Vaxcyte Inc, 2021
Otitis Media - Pipeline by Vyome Therapeutics Inc, 2021
Otitis Media - Pipeline by Yuhan Corp, 2021
Otitis Media - Dormant Projects, 2021